Retinal implants have gained increasing interest since it was demonstrated in acute trials that completely blind subjects do have light perception upon electrical stimulation of the inner surface ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...

Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...

The implant was also shown to be safe and well ... Charles Wykoff, director of research at Retinal Consultants of Texas and an investigator in the Encelto clinical trials, said in Neurotech ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) ...

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

The global Dental Implants and Prosthetics Market, valued at US$11.61 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$12.57 billion in 2025 and an impressive US$18.79 ...

Cortigent will focus on neuromodulation devices while Vivani presses ahead with its weight loss drug implant. Vivani Medical ...

The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).